Bio-Thera Solutions, Ltd. — Investor Relations & Filings
About Bio-Thera Solutions, Ltd.
Bio-Thera Solutions, Ltd. is a biopharmaceutical company dedicated to the research and development of innovative therapeutics and high-quality biosimilars. The company focuses on addressing serious medical conditions across oncology, autoimmune, and cardiovascular therapeutic areas. Its portfolio includes several approved biosimilars, such as QLETLI (adalimumab), POBEVCY (bevacizumab), and TOFIDENCE (tocilizumab), alongside a robust pipeline of novel drug candidates, including antibody-drug conjugates (ADCs) and monoclonal antibodies. Bio-Thera utilizes advanced technology platforms to streamline the drug discovery and development process, aiming to expand global access to essential biologic medicines. The organization maintains a commitment to rigorous clinical standards and international regulatory compliance to deliver effective treatment options for patients worldwide.
Recent filings
| Filing | Released | Lang | Actions |
|---|---|---|---|
| 百奥泰2025年度会计师事务所履职情况评估报告 | 2026-04-27 | Chinese | |
| 百奥泰2025年度独立董事述职报告（柳建华） | 2026-04-27 | Chinese | |
| 百奥泰2026年度“提质增效重回报”专项行动方案 | 2026-04-27 | Chinese | |
| 百奥泰2025年度董事会审计委员会履职情况报告 | 2026-04-27 | Chinese | |
| 百奥泰 关于全资子公司与关联方签订建设工程施工合同暨关联交易的公告 | 2026-04-27 | Chinese | |
| 百奥泰 关于续聘会计师事务所的公告 | 2026-04-27 | Chinese |
| ID | Filing | Released | Lang | Actions | |
|---|---|---|---|---|---|
|
2026
15 filings
| |||||
| 39231013 | 百奥泰2025年度会计师事务所履职情况评估报告 | 2026-04-27 | Chinese | ||
| 39231005 | 百奥泰2025年度独立董事述职报告（柳建华） | 2026-04-27 | Chinese | ||
| 39230996 | 百奥泰2026年度“提质增效重回报”专项行动方案 | 2026-04-27 | Chinese | ||
| 39230995 | 百奥泰2025年度董事会审计委员会履职情况报告 | 2026-04-27 | Chinese | ||
| 39230987 | 百奥泰 关于全资子公司与关联方签订建设工程施工合同暨关联交易的公告 | 2026-04-27 | Chinese | ||
| 39230977 | 百奥泰 关于续聘会计师事务所的公告 | 2026-04-27 | Chinese | ||
| 39230969 | 百奥泰2025年度非经营性资金占用及其他关联资金往来情况的专项报告 | 2026-04-27 | Chinese | ||
| 39230942 | 百奥泰 2026年第一季度报告 | 2026-04-27 | Chinese | ||
| 39230934 | 百奥泰2026年第二次临时股东会会议资料 | 2026-04-20 | Chinese | ||
| 39230928 | 百奥泰 关于转让药品品种权益及相关资产与业务的公告 | 2026-04-14 | Chinese | ||
| 34919906 | 百奥泰 关于召开2026年第二次临时股东会的通知 | 2026-04-14 | Chinese | ||
| 34860787 | 中国国际金融股份有限公司关于百奥泰生物制药股份有限公司使用部分暂时闲置募集资金及部分自有资金进行现金管理的核查意见 | 2026-04-14 | Chinese | ||
| 34849696 | 百奥泰 关于使用部分暂时闲置募集资金及部分自有资金进行现金管理的公告 | 2026-04-14 | Chinese | ||
| 39230924 | 百奥泰 自愿披露关于BAT3306联合BAT8008治疗晚期实体瘤获得药物临床试验批准通知书的公告 | 2026-04-02 | Chinese | ||
| 39230920 | 百奥泰 自愿披露关于与STADA就BAT2506（戈利木单抗）注射液签署授权许可与商业化协议收到里程碑付款的进展公告 | 2026-03-26 | Chinese | ||
Market data
Market data not available
Price history
Peer group · Manufacture of pharmaceuticals, medicinal chemical and botanical products
| Company | Ticker | Country | Sector |
|---|---|---|---|
|
13260917 Canada Inc.
Biotech developing oral small molecules to restore muscle s…
|
MSCL | CA | Manufacturing |
|
1608557 Ontario Inc.
Biopharmaceutical company dedicated to R&D, discovery, and …
|
OTROQ | CA | Manufacturing |
|
3B BlackBio Dx Limited
Develops molecular diagnostic kits for oncology, infectious…
|
3BBLACKBIO | IN | Manufacturing |
|
3D Medicines Inc.
Commercial-stage biopharma specializing in next-generation …
|
1244 | HK | Manufacturing |
|
3SBio Inc.
Biopharmaceutical enterprise specializing in R&D, productio…
|
1530 | KY | Manufacturing |
|
4BASEBIO PLC
Manufactures GMP-grade synthetic DNA for next-generation th…
|
4BB | GB | Manufacturing |
|
4D Molecular Therapeutics, Inc.
Develops genetic medicines using AAV vectors for ophthalmol…
|
FDMT | US | Manufacturing |
|
4Front Ventures Corp.
Vertically integrated cannabis operator managing cultivatio…
|
FFNT | CA | Manufacturing |
|
4SC AG
Biopharmaceutical company with no products under developmen…
|
VSC | DE | Manufacturing |
|
60 DEGREES PHARMACEUTICALS, INC.
Develops and commercializes medicines for infectious diseas…
|
SXTP | US | Manufacturing |
Bio-Thera Solutions, Ltd. via the API
Pull this company's filings, identifiers, and metadata as JSON or Markdown. Authenticate with your API key, then query by company ID, ISIN, or LEI. Full schema documented in the OpenAPI spec.
Endpoints
| GET | /api/companies/58210/ | Company identity, sector, listing, identifiers |
| GET | /api/filings/?company=58210 | Paginated list of all filings (filterable by type, date, language) |
| GET | /api/filings/{id}/ | Single filing — metadata, document URL, processing status |
| GET | /api/filings/{id}/markdown/ | Filing content as Markdown (PDF → text/tables/figures) |
| GET | /api/isins/?company=58210 | All ISINs registered to this company |
| GET | /api/filing-types/ | Reference: every filing-type code + category |
cURL
$ curl https://api.financialreports.eu/api/filings/?company=58210 \ -H "x-api-key: $FR_API_KEY" \ -H "Accept: application/json"
Python
import requests r = requests.get( "https://api.financialreports.eu/api/filings/", params={"company": 58210}, headers={"x-api-key": API_KEY}, ) filings = r.json()["results"]
MCP server
// MCP server URL https://mcp.financialfilings.com/mcp // Once connected, the LLM can query this company directly: "Pull the latest 5 filings for Bio-Thera Solutions, Ltd. (id: 58210)"
Report missing filing
Can't find a specific document? Let us know and we'll add it within 24 hours.